AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data
admin 18th September 2018 Uncategorised 0AstraZeneca struck out in May in trying to expand severe eosinophilic asthma drug Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
More: AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data
Source: fierce